New drug duo shows promise for rare blood cancer
NCT ID NCT04763616
First seen May 04, 2026 · Last updated May 20, 2026 · Updated 2 times
Summary
This study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with a rare type of blood cancer called NK/T-cell lymphoma that had come back or not responded to prior treatment. The goal was to see if the combo could shrink tumors and control the disease. While not a cure, the approach aims to offer a new treatment option for patients with limited choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER/T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Samsung Medical Center
Seoul, Kangnamgu, 06351, South Korea
Conditions
Explore the condition pages connected to this study.